BioMarin Pharmaceutical

BioMarin is almost entirely directed at rare genetic diseases — sometimes called ultra-orphan conditions — where the global patient population can be in the low thousands. This is a departure from larger biotechs that balance rare-disease assets with broad primary-care pipelines. The strategy relies on high per-patient pricing and FDA orphan drug exclusivity periods to generate returns, rather than large prescription volumes.

Vimizim for Morquio A syndrome has historically been the largest contributor, alongside Naglazyme for MPS VI, Kuvan and Palynziq for phenylketonuria (PKU), and Brineura for CLN2 disease. In 2023, the approval of Roctavian, a gene therapy for severe hemophilia A, added a new high-value asset to the portfolio. The revenue mix is geographically split across the United States, Europe, Latin America, and rest-of-world markets.

The FDA's orphan drug designation provides seven years of market exclusivity upon approval, along with tax credits and waived application fees for many products. BioMarin strategically targets conditions that often have no approved therapy, meaning the regulatory hurdle is balanced by a near-complete lack of competition for years. However, the clinical trials are inherently small, and the agency's review bar for safety and efficacy in tiny patient populations can produce unpredictable outcomes — as seen when the company initially withdrew its hemophilia A gene therapy application in 2020 before securing approval in 2023.

BioMarin's headquarters and a key research facility are in San Rafael, California, with an additional research center in Novato, California. The company operates a large-scale biologics manufacturing plant in Shanbally, County Cork, Ireland. Commercial operations cover over 75 countries through subsidiaries and distributors, with major revenue contributions from the United States, Germany, the United Kingdom, France, Italy, and Brazil.

Yes. Roctavian, approved in the US in 2023 and conditionally approved in Europe in 2022, is the first gene therapy for severe hemophilia A. It uses an AAV5 vector to deliver a functional copy of the Factor VIII gene. The approval marked a decade-long, precedent-setting effort, and the company is now building commercial infrastructure for a one-time infusion that can cost upwards of $2.9 million per patient in the United States.

Jean-Jacques Bienaimé has served as Chairman and CEO since 2005, after previous CEO roles at Genencor and executive positions at Rhône-Poulenc Rorer. Alexander Hardy joined as President and CEO in December 2023 from Roche's Genentech unit, succeeding Bienaimé in the chief executive role. Brian Mueller remains CFO, and the firm's research organization is led by Greg Friberg, SVP and Chief R&D Officer for the Rare Disease Therapeutic Area.

BioMarin operates its own biologics manufacturing facilities rather than outsourcing to contract manufacturers. The main production site is in Shanbally, Ireland, which produces bulk drug substance for the enzyme replacement therapies. A second facility in Novato, California, handles gene therapy vector production, including the AAV5 material for Roctavian. In 2024, the company initiated a plan to increase manufacturing efficiency as part of its broader cost-reduction restructuring.